5 completed, 2 recruiting. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow End Stage Kidney Disease: new trials by email Literature Review of End Stage Kidney Disease trials Research Report on End Stage Kidney Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Empagliflozin 25 MG - Peritoneal Dialysis Complication, End Stage Kidney Disease | Phase 3 | Recruiting | University Health Network, Toronto | 20 | 2024-09-01 | 2026-05-01 |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) CSL300, Placebo - End Stage Kidney Disease | Phase 2 / Phase 3 | Recruiting | CSL Behring | 3110 | 2024-04-27 | 2026-09-21 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery Sirolimus - Complication of Renal Dialysis, End Stage Renal Disease | Phase 3 | Completed | Vascular Therapies, Inc. | 136 | 2022-08-26 | 2026-10-06 |
| Better Evidence for Selecting Transplant Fluids Plasma-Lyte 148 (approx. pH 7.4) IV Infusion, 0.9% SODIUM CHLORIDE 9g/L injection BP - End Stage Kidney Disease, Delayed Graft Function | Phase 3 | Completed | The University of Queensland | 808 | 2018-01-26 | 2024-10-15 |
| Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI) - Complication of Renal Dialysis, End Stage Renal Disease | Phase 3 | Completed | Vascular Therapies, Inc. | 269 | 2015-11-01 | 2025-10-09 |
| Effect of N-acetylcysteine (NAC) on Hydrogen Sulfide (H2S) in Chronic Kidney Disease (CKD) N-acetylcysteine - Chronic Kidney Disease, Chronic Kidney Failure | Phase 3 | Completed | A.C. Abrahams | 28 | 2011-07-01 | 2012-10-26 |
Kidney Failure, Chronic (7) · Arteriovenous Fistula (2) · Renal Insufficiency, Chronic (2) · Atherosclerosis (1) · Coronary Artery Disease (1) · Delayed Graft Function (1) · Diabetes Mellitus (1) · Hyperparathyroidism, Secondary (1) · Myocardial Infarction (1) · Peripheral Arterial Disease (1)
Chronic Disease (7) · Disease Attributes (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Kidney Diseases (7) · Male Urogenital Diseases (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Renal Insufficiency (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Renal Insufficiency, Chronic (5) · Cardiovascular Diseases (3) · Vascular Diseases (3) · Arteriovenous Malformations (2)
Sirolimus (2) · Acetylcysteine (1) · Infusions, Intravenous (1) · Plasma-lyte 148 (1) · Plasmalyte A (1) · Saline Solution (1) · Sodium Chloride (1) · clazakizumab (1) · empagliflozin (1)
Vascular Therapies, Inc. (2) · A.C. Abrahams (1) · CSL Behring (1) · Pathalys Pharma (1) · The University of Queensland (1) · University Health Network, Toronto (1)
United States (4) · Australia (2) · Bulgaria (2) · Canada (2) · Netherlands (2) · Poland (2) · Portugal (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · China (1) · Czechia (1)
Sriram Iyer, MD (2) · A C Abrahams, MD (1) · M C Verhaar, MD, PhD (1) · Michael Collins, MBChB,FRACP,PhD (1) · Steven Chadban, BMed(hons),FRACP,PhD (1) · Sunita KS Singh, MD MSc FRCPC (1)
PMID 32450917, PMID 35042554, PMID 37343576, PMID 38796655
2023 (1)